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Available online 29 March 2019Background: Atrial fibrillation (AF) is a major preventable risk factor for stroke and may be silent in elderly
individuals who are at especially high risk. This paper describes the first phase of implementation of a clinical
AF detection programme in a community setting. Objectiveswere (i) to determine the feasibility of using a hand-
held ECG recording system for AF detection among individuals aged 65 years or more, who have cardiovascular
risk factors. (ii) to estimate the yield of previously undiagnosed atrial fibrillation cases, and the proportion of
these who would be suitable for oral anticoagulation.
Methods: a handheld ECG monitor was placed in each of 23 primary care practices across Scotland. Eligible
patients attending for annual health checks had ECGs recorded, and the ECGs were transmitted and interpreted
by two senior cardiologists. ECG quality was rated, and an adjudication made on the rhythm. For patients
confirmed with AF, stroke and bleeding risk were estimated using CHA2DS2-VASc and HAS-BLED scoring tools.
Results: single lead ECGs were recorded in 1805 patients (703 female and 1102 male), mean (SD) age 74.9 (7.1)
years. Rhythm regularity could be assessed in 98.7% of ECGs recorded. 92 patients (5.1%) were found to have AF.
Median [range]CHA2DS2-VASc score was 4 ([2–7) and median [range] HAS-BLED score was 2 (1–5).
Conclusion: handheld ECG recording can be used to identify AF in the primary care setting,withminimal training.
The yield was relatively high.







Atrial fibrillation is a major risk factor for stroke. Left atrial append-
age thrombus formation occurs because of atrial stasis and because of
changes in atrial wall composition [1]. Platelet activity increases and
the coagulation cascades are activated when atrial fibrillation occurs.
Stroke risk is especially prevalent in patientswith heart failure, diabetes,
hypertension, and vascular disease. This risk increases with age, and
females are more likely to suffer stroke than males after adjustment
for other risk factors. Stroke risk is modifiable through the use of antico-
agulant drugs. Warfarin substantially reduces stroke risk in atrial fibril-
lation [2]. Direct oral anticoagulant (DOAC)drugs are at least as effective
as warfarin and are supplanting the use of warfarin for this indication
[3–6]
In the elderly population, atrial fibrillation is often asymptomatic or
producesmild symptomswhich do not prompt self-referral. Individualsoyal Infirmary of Edinburgh, 51
R. Grubb).
r B.V. All rights reserved.with atrialfibrillationwhoare asymptomaticwhen they presented have
a threefold higher incidence of prior stroke than do those who present
with symptomatic atrial fibrillation [7]. This age group is at especially
high risk of stroke when atrial fibrillation occurs, and many patients
are likely to benefit from anticoagulants. In one study of asymptomatic,
untreated individuals with atrial fibrillation, the stroke rate over
1.5 years follow-upwas approximately 4% comparedwith 1% for an oth-
erwise similar group who did not have atrial fibrillation. Undiagnosed
atrial fibrillation is associatedwith high overall mortality rate compared
with similar individuals without atrial fibrillation [8,9].
At present, atrial fibrillation is not identified in a systematic manner
in primary care in Scotland. Pulse checking is a useful method of identi-
fying atrial fibrillation but is not as reliable as the ECG [10]. The
European Society of Cardiology currently recommends the use of an
ECG rhythm strip to pulse palpation because of its limitations [11].
Within United KingdomQuality and Outcomes Framework (QOF) stan-
dards, patients with chronic diseases e.g. cerebrovascular disease, dia-
betes, hypertension, vascular disease and chronic kidney disease
(stage 3 and above) have been seen annually in primary care. These pa-
tients form an ideal potential target population for atrial fibrillation
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aged N65 years are targetedwhen they have other risk factors for stroke,
or if and older age threshold (e.g. 70 years) is selected [12].
New technologies allow for easier identification of patients with
atrial fibrillation. The 12 lead electrocardiogram is the gold standard
for confirming this diagnosis, but for screening a simple single lead
electrocardiogram can be used to identify P-waves and to assess the
regularity of the rhythm. Recently, an adapter unit has been developed
for smartphones and handheld computing devices (AliveCor®) which
allows recording of such ECGwaveforms [13]. These devices are primar-
ily used as event recorders for patients with palpitation, but can also be
used to record ECG data for screening for silent arrhythmias.
To maximise yield among individuals with moderate to high annual
stroke risk, it makes sense to screen among older patients and/or those
with other risk factors for stroke. Single timepoint screening of individ-
uals over 65 years of age in the general population identifies (mostly
persistent) atrial fibrillation in 1.4% of cases [14]. The European Society
of Cardiology recommend opportunistic screening of all such individ-
uals when medical contact is made [11]. When individuals over
75 years of age are screened with repeat recordings, a 3% yield is seen
and this increases if individuals with known cardiovascular risk factors
are selected [15–17].
This manuscript describes initial clinical experience in the imple-
mentation of an atrial fibrillation case-finding strategy among 22 pri-
mary care (general) practices across Scotland. This work was
commissioned by the (Scottish)National Advisory committee for Stroke
and the National Advisory Committee for Heart Disease, and was
supported by the Digital Health Institute.
The objectives of this pilot clinical service were (i) to determine
within the United Kingdom healthcare setting, the feasibility of screen-
ing for atrial fibrillation in primary care using a single lead ECGmonitor,
among individuals aged 65 years or older who have one ormore cardio-
vascular risk factors; (ii) to estimate the yield of new atrial fibrillation
cases, and the proportion of those patients who would be suitable for
oral anticoagulation using standard risk scoring systems and bleeding
risk systems.
2. Methods
(i) Selection of practices
A handheld ECG monitor unit was placed in each of twenty-three primary care
practices in Scotland (three additional practices were included later on, because of poor
recruitment from some practices). Practices were selected by lead cardiologists based in
SE Scotland, West of Scotland, Tayside, Grampian and Fife. Each primary care practice
had a designated member of staff responsible for ECG monitoring in that practice; in
two cases this was a general practitioner and in all other cases this was a practice nurse.
A single training session was provided by the study co-ordinator for each practice, in
which single lead ECG recording techniquewas taught tomaximise ECG recording quality.
A weekly upload of ECG recordings was set up from each practice to the lead cardiologist.
This manuscript describes the outcome of implementation of a clinical service and not a
clinical research study. However, informed consent was obtained from patients and the
implementation protocol conforms to the ethical guidelines of the 1975 Declaration of
Helsinki.
(ii) Inclusion criteria
Patients aged 65 years or greater, attending their primary care practice for annual
chronic disease assessment, were eligible for screening. Patients also had to have one or
more of the following stroke risk factors: heart failure, hypertension, diabetes mellitus,
previous stroke or transient ischaemic attack, peripheral or carotid arterial disease.
(iii) Exclusion criteria
Patients with a prior documented history of any atrial fibrillation episode were
excluded.
(iv) ECG recording
30 second ECG recordings weremade on patients with at least one risk factor in addi-
tion to age from the CHA2DS2-VASc scoring system. Patients with a prior history of AF
were not included. These were patients attending for annual visits under the QOF chronicdiseases recommendations. ECGs were recorded using an AliveCor® recorder attached to
an Apple® iPod Touch® 5 handheld device. ECGswere recorded after handwashing, with
hands rested on a table, away frommains equipment, tominimise noise. A uniquenumber
was assigned to each patient, and no patient-identifiable data were recorded on devices.
ECG data and identifiers were uploaded onto the AliveCor (Kardia) server after each ses-
sion. Anonymised ECG recordings were then available for analysis by the lead cardiologist
for each region. In this pilot we did not utilise an automated ECG interpretation algorithm.
(v) Confirmation of diagnosis of atrial fibrillation
The lead cardiologist for each region received ECGs via the AliveCor (Kardia) server,
using a secure protocol. The cardiologist adjudicated on whether or not the ECG was of
interpretable quality, and if interpretable, whether atrial fibrillation was present or not.*
Patients with a provisional diagnosis of atrial fibrillation based on the handheld ECG re-
cording were referred for a 12 lead ECG as per local protocols. All ECGs were examined
by a second cardiologist, and in cases inwhich therewas disagreement about the presence
or absence of atrial fibrillation, practices were asked to regard the patient as having
suspected atrial fibrillation. As local practice varies between regions in Scotland, the
screening protocol did not specify how patients were to be managed after AF detection,
and general practitioners were recommended to follow their normal local practice for
managing a patient with suspected AF.
(vi) Data collection
Additional medical history data were collected for all patients identified to have atrial
fibrillation. These data were collected to enable the investigators to calculate stroke and
bleeding risk using the following scoring systems [18–21]:
CHA2DS2-VASc – used to assess stroke risk in patients with nonvalvular atrial
fibrillation.
HAS-BLED – accounts for some CHA2DS2-VASc risk factors, plus bleeding history, labile
INR, abnormal liver and renal function, and current hypertension in estimating bleeding
risk from oral anticoagulation.
Anticoagulant and antiplatelet drug history were also collected.
2.1. Outcome measures
The main outcome measure was:
- prevalence of atrial fibrillation among individuals aged N65 years who have other risk
factors for stroke (as encompassed in the CHA2DS2-VASc scoring system)
Secondary pre-defined outcome measures were:
- proportion of recorded ECGs of interpretable quality
- proportion of patients with atrial fibrillation who would be suitable for oral
anticoagulation
- proportion of new patients with HAS-BLED score of 3 or more points whomay be un-
suitable for oral anticoagulation because of bleeding risk
(vii) Assessment of quality of handheld ECG recordings
The quality of unfiltered ECG recordingswas graded by the local cardiologist against a
set of predefined criteria as follows: grade 1: cannot be interpreted; grade 2: noisy base-
line. P-waves may be unclear if present, but regularity of rhythm can be assessed; grade
3: moderate baseline interference or noise. P-waves clear if present; grade 4: minor inter-
ference or noise; grade 5: no noise, very clear ECG.
2.2. Statistical analysis
Descriptive statistics are used to present CHA2DS2-VASc and HAS-BLED scores for the
patients identified with atrial fibrillation. As distributions were likely to be positively
skewed we present data as median (range).
3. Results
3.1. Data acquisition
Practice training visits took place between June and July 2014. The
screening pilot commenced in August 2014 and was completed in
October 2015. 2124 patients were identified for screening. Single lead
ECGs were recorded and analysed in 1805 patients (703 female and
1102male),mean (SD) age 74.9 (7.1) years. All patientswere confirmed
to have at least one risk factor in addition to age from the CHA2DS2-VASc
scoring system.
In 319 cases ECG data were missing because of incorrect entry of
study data onto the recorder, or because of accidental deletion of ECGs
before uploading. Most of the data loss occurred in the first twomonths
of the study.
Table 2
HAS-BLED scores of patients identified to have atrial fibrillation from handheld ECG
recording.
RISK FACTOR Number of patients Percentage
Current systolic BP N 160 mmHg 8 9.1
Liver/renal dysfunction 21 23.8
Previous stroke 14 15.9
Bleeding tendency 2 2.3
Labile INR 0 0
Age 65 years or greater 88 100
Drugs (NSAID/antiplatelet) 41 46.5
Alcohol misuse 0 0
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fibrillation. 175 patients (9.7%) had at least two (atrial or ventricular)
ectopic beats during the 30 s recording.
Among the patients confirmed to have atrial fibrillation, the break-
downof CHA2DS2-VASc scores is summarised in Table 1. Thebreakdown
of HAS-BLED scores is summarised in Table 2.
3.2. Qualitative assessment of handheld ECG recordings
Rhythm regularity could be assessed in 1780 (98.7%) cases. In 427
(23.7%) the ECG quality was excellent. Overall, mean (SD) ECG quality
was 3.67 (1.01). There was little variation between regions in ECG qual-
ity, with mean (SD) values for each region as follows: Fife 3.84 (0.94),
Lothian 3.68 (1.03), West of Scotland 3.61 (1.01), Grampian 3.67
(1.05), Tayside 3.51 (1.04). P-waves could be seen among patients
identified not to have atrial fibrillation in 94% of cases.
3.3. Stroke risk
Future annual stroke risk was estimated using the CHA2DS2-VASC
score.Median [range]CHA2DS2-VASc scorewas4 (2–7). The distribution
of CHA2DS2-VASC scores is shown in Fig. 1.
No patients had CHA2DS2-VASC score of 0 or 1 point because the
predefined screening criteria stipulated that patients should be age
65 years or greater and have one other CHA2DS2-VASC component risk
factor. Median (range) CHA2DS2-VASC score of those with AF was 4
(2–7) and of those without AF was 4 (2–7). Each patient was assigned
an annual bleeding risk based on data from the original validation
study for CHA2DS2-VASC. Median estimated annual stroke risk for pa-
tients identified to have atrial fibrillation was 4 (2.2–9.8) percent. The
distribution of individual stroke risk factors within the CHA2DS2-VASC
score are shown in Table 1. Excluding age, which was an inclusion
criterion for screening, hypertension and vascular disease were the
most prevalent risk factors.
3.4. Bleeding risk
Future bleeding risk was estimated using the HAS-BLED score.
Median [range] HAS-BLED score was 2 (1–5). The distribution of
HAS-BLED scores is shown in Fig. 2.
Median HAS-BLED score was 2 (1–5). Each patient was assigned an
annual bleeding risk based on data from the Euro Heart Survey from
which the HAS-BLED score was derivedPisters 2010. Median estimated
annual stroke risk for patients identified to have atrial fibrillation was
1.8 (1.02–12.5) percent. The prevalence of bleeding risk factors within
the HAS-BLED score are shown in Table 2. Excluding age, which was
an inclusion criterion for screening, hepatic or renal dysfunction and
previous stroke were the most prevalent risk factors.
3.5. Stroke risk among patients with high estimated bleeding risk
19 patients (22%) of patients identified with new atrial fibrillation
had HAS-BLED score of three points or greater. Patients withTable 1
CHA2DS2-VASc scores of patients identified to have atrial fibrillation from handheld ECG
recording.
Risk factor Number Percentage
Congestive heart failure 15 17.0
Hypertension 65 73.8
Age 65–74 years 36 40.9
Age N 74 years 52 59.1
Diabetes mellitus 26 29.5
Stroke or TIA 14 15.9
Vascular disease 32 36.6
Female gender 33 37.5HAS-BLED score at this level are considered at increased risk of major
bleeding with warfarin (N5 major bleeding events per 100 patient
years) [21]. The median CHA2DS2-VASC score of patients who had in-
creased bleeding risk was 5 (4–7), identifying a group of patients in
whom anticoagulation is likely still to be considered despite increased
bleeding risk. The median (range) HAS-BLED score of patients with
CHA2DS2-VASc score 1–3 points was 1 (1–2); with CHA2DS2-VASc
score 4–5 points was 2 (1–4) and with CHA2DS2-VASc score 6–7 points
was 3 (1–5).
3.6. Oral anticoagulant prescription
Of the 92 patients identified to have AF, 74 (80%)were prescribed an
oral anticoagulant after diagnosis. Ten patients were not recommended
anticoagulation because of perceived high bleeding risk and six declined
anticoagulation.
4. Discussion
This pilot has examined the feasibility of implementing a screening
programme for atrial fibrillation using a handheld, smartphone-based
ECG recorder, among individuals aged N65 years who have risk factors
for stroke. Once initial training and technical obstacles are overcome,
it is feasible to use this technology to identify patients with previously
undiagnosed atrial fibrillation in the community.
ECG quality was acceptable for identifying atrial fibrillation in most
cases, but might be improved with refresher training sessions. In
98.7% of cases the ECG was of sufficient quality to identify an irregular
rhythm. In 12.9% of cases the ECG quality was graded ‘2’ and therefore
not optimal. With the introduction of an automated algorithm to
check ECG quality and identify atrial fibrillation, repeat ECG recording
would be prompted to the user. Such algorithms are associated with
sensitivity up to 99% and specificity up to 97% [22,23,24].
The yield for previously unidentified atrial fibrillation was 5%.While
considerably greater than that seen in other population studies, such a
high yield may partly be explained by the inclusion of a relatively high
percentage of patients with risk factors such as diabetes or hyperten-
sion. In one study the prevalence of ECG observable atrial fibrillation
in hypertensive patients of age 65 or greater was 6.7% [25]. In Engdahl's
study of patients aged 75–76 years using the Zenicor device, AFwas de-
tected in N7% in patients who had one or more non age CHA2DS2-VASc
risk factor. In these studies the high rate of detection of AFmay be partly
due to additional comorbidities and due to the methods of screening in
which ECGs were recorded at multiple time points with a significantly
higher detection rate than a single ECG [15,16,25]. The prevalence of
AF in our cohort is considerably higher than that found in the SAFE
study, but that study did not require pre-existing risk factors such as hy-
pertension, diabetes or heart failure which would tend to increase the
prevalence of AF [26]. The prevalence is also higher than that cited by
Lowres et al. in a systematic review of 30 studies using a variety of de-
tection methods [14]. Again these studies did not necessarily pre-
specify pre-existing stroke risk factors, and detection methods such as




















Fig. 1. Distribution of CHA2DS2-VASC scores among patients with newly identified atrial fibrillation.
97N.R. Grubb et al. / International Journal of Cardiology 288 (2019) 94–99the high prevalence of AF found in our cohort suggests under-detection
of AF in primary care in Scotland. The yield for multiple ectopic beats
was nearly 10%, and this indicates that methods which rely on identify-
ing pulse irregularity alone (such as pulse checks, or blood pressure
monitors with irregularity detection) may be prone to false positive
error in this population. Among patients with atrial fibrillation the
median CHA2DS2-VASC scorewas 4 points andmedian predicted annual
stroke risk was 4%.
The University of Aberdeen Department of Health Economics are
analysing the data from this pilot in detail, to make an estimate of the
cost per case of atrial fibrillation identified, cost per stroke prevented,
and the estimated additional burden from bleeding if patients are
treated with anticoagulants. Below is a basic interpretation of the data
which is preliminary only:
For every 1000 patients screened, 50 patients will be identifiedwith
previously unknown atrial fibrillation. With a predicted median annual
stroke risk of 4%, this would mean that 2.4 strokes would occur every
year if these patients went untreated (this figure accounts for the fact
that stroke risk increases steeply when the CHA2DS2-VASC score is
greater than the median). Anticoagulation with warfarin is known to
reduce stroke risk by 64% relative to placebo treated patients, so warfa-





















Fig. 2. Distribution of HAS-BLED scores among patuse of the novel oral anticoagulants (NOACs) dabigatran or apixaban is
associated with approximately 20% further stroke risk reduction over
warfarin [3,4]. Thus, treatment of all patients identifiedwith atrialfibril-
lation from a screening cohort of 1000 could prevent 1.7–1.8 strokes per
year, or potentially up to 17–18 strokes over ten years of treatment.
Expected bleeding risk with oral anticoagulants also needs to be
taken into account; this is defined as bleeding requiring transfusion of
two or more units of packed red cells (or a fall in haemoglobin level of
at least 2 g per decilitre), or intracranial bleeding. With NOACs the ex-
pectedmajor bleeding riskwould be 2.1% per year, or 21major bleeding
events over ten years requiring transfusion. The most important end-
point is intracranial bleeding, and based on data from the ARISTOTLE
trial with apixaban, and RELY trial with dabigatran, expected risk
would be 0.24% per year of treatment, or up to 2.4 intracranial bleeding
events over 10 years [3,5].
Future studies need to examine the relationship between atrial
fibrillation burden and stroke risk as for patients who have low burden
intermittent rather than persistent atrial fibrillation, the risk- benefit
balance of anticoagulation is less clear [28]. Studies of atrial fibrillation
burden and stroke risk, using ‘atrial high rate episodes’ detected from
implantable devices, suggest that any episodes of five minutes or
greater is associated with increased risk of death or stroke [28]. The3 4 5
ED score
ients with newly identified atrial fibrillation.
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not direct [29]. Thus future case finding initiatives which focus on
paroxysmal rather than persistent atrial fibrillation need to account
for the complex and nonlinear relationship between AF burden and
stroke risk.
Implementation of screening technologies has been explored by the
Scottish Government Cross Party Working group on Atrial Fibrillation
[30,31]. Implementation of technology to provide a clinical case finding
service requires several steps. Firstly, it is best integrated into a primary
care system in which patients with the cardiovascular risk factors
encompassed by CHA2DS2-VASc are seen at least annually, as is the
case in the United Kingdom. This has historically been done via the
Quality and Outcomes Framework, which until 2017 provided an incen-
tive mechanism for all primary care practices to offer review to all
patients over 65 years of age annually and to assess chronic disease
prevalence [32]. In Scotland 95% of practices participated fully in
2016–2017. In the future a similar or improved system needs to be
put in place for identification and recall of these patients. This clinical
pilot has identified the prevalence of undetected atrial fibrillation in a
population not subject to systematic case finding, so the prevalence fig-
ure is known whereas the annual incidence is not. The frequency of
screening will affect cost-effectiveness but annual screening may be
tested in the first instance. Single session training of primary care nurses
appears to produce acceptable ECG quality over the first year but re-
fresher training may be required to maintain quality. ECG recording
and stroke and bleeding score risk calculation will require approxi-
mately tenminutes of nurse time per patient. The use of high sensitivity
and specificity automated ECG analysis will eliminate consultant costs
for most single lead ECG screening. Once AF has been identified rapid
referral for 12 lead ECGconfirmation of atrialfibrillation is needed, and in-
frastructure put in place for ongoing investigation and management of
those patients, for example through arrhythmia nurse specialist-led atrial
fibrillation clinics with access to echocardiography and cardiologist re-
view. Cardiologist recommendations at the time of diagnosis confirma-
tion may help optimise the rate of anticoagulant use.
5. Conclusion
Screening for AF in primary care in the Scottish population, using
handheld ECG monitors, is feasible and a clinically important yield is
likely to result. It is possible that AF is underdiagnosed in this population
compared with others studied. Upscaling will require significant infra-
structure and resource planning.
5.1. Study limitations
The diagnostic accuracy of the device used could not be assessed in
this study but has been well described by other investigators [22–24].
AF detectionwas carried out on on-consecutive patients in a clinical set-
ting in which no additional staffing or infrastructure could be provided.
The investigators relied on the ability of practice nurses to identify and
record ECGs on patients when clinical time permitted. It is possible
that selection bias occurred. The unusually high yield of AF found in
this population would need to be confirmed in a subsequent analysis
of yield as the clinical service is developed.
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